{"id":"W4361245262","doi":"10.1093/oncolo/oyad008","title":"Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"Janssen Biotech; Janssen Research and Development; Amgen; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; UroGen Pharma; Dendreon Pharmaceuticals; Progenics Pharmaceuticals; Sanofi; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Androgen receptor; Abiraterone; Androgen deprivation therapy; Internal medicine; Oncology; Cancer research; PARP1; Testosterone (patch); Pharmacology; Cancer; Poly ADP ribose polymerase; Polymerase; Gene; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001268402,0.0008746281,0.001149961,0.000285911,0.0002942241,0.001067195,0.000560033,0.000778311,0.002050502],"category_scores_gemma":[0.0006895123,0.0002860675,0.0009991989,0.0003039113,0.0004800908,0.000527447,0.0002957317,0.002134278,0.0005899016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005908044,"about_ca_system_score_gemma":0.001716927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007264405,"about_ca_topic_score_gemma":0.002005286,"domain_scores_codex":[0.9996555,0.000150168,0.00002164204,0.00004820491,0.00006659737,0.00005785638],"domain_scores_gemma":[0.9995853,0.00005437797,0.00005574597,0.00002944714,0.00004336349,0.0002317262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2968884,0.1220207,0.01361456,0.002356813,0.003185472,0.0009157005,0.0006023044,0.009672489,0.09573486,0.001572957,0.0239269,0.429509],"study_design_scores_gemma":[0.419707,0.5005544,0.0201628,0.0002046552,0.001093691,0.001800351,0.000137817,0.003820205,0.01535861,0.0009911187,0.03608557,0.00008381259],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679869,0.01169923,0.002260684,0.001702633,0.0003140009,0.004715495,0.003629483,0.0002415105,0.007450135],"genre_scores_gemma":[0.9618052,0.01069118,0.004534277,0.003421222,0.0003395891,0.004080006,0.008622802,0.00006660849,0.006439039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002050502,"threshold_uncertainty_score":0.006859541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08989458193043044,"score_gpt":0.4177456472270286,"score_spread":0.3278510652965981,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}